Menu Login / Registration Search

CLIA Chlamydia trachomatis IgM

Chemiluminescence kit for the detection of IgM antibodies to Chlamydia trachomatis in human serum or plasma

Catalog Number: CL-ChtM100
Size: 100 tests
Regulatory status: CE IVD
Clinical topic: Infectious Diseases
Diagnostic panel: Sexually Transmitted Infections (STIs)
CLIA Chlamydia trachomatis IgM
  • Detection of IgM antibodies to Chlamydia trachomatis
  • Screening test intended for sexually active women age 25 or younger, pregnant women, and women and man at high risk
  • Identification of chlamydial infection
  • Intended for human serum and citrate plasma
  • A mixture of highly specific recombinant antigens was used to achieve high assay specificity

Chlamydia is caused by the gram-negative, obligate intracellular bacterium Chlamydia trachomatis. Globally, it is the most prevalent sexually transmitted bacterial infection. The organism causes genitourinary infections in women and men, the disease often remains asymptomatic. Sexually active young people between 15 and 30 years of age are most at risk of chlamydia. The most common complications are pelvic inflammatory disease (PID) and salpingitis, conditions that can lead to infertility in both men and women and extra-uterine pregnancies. Cervical chlamydia infection is currently considered to be one of the risk factors for uterine cervix carcinoma.

Once detected, the infection is easily treated by a short course of antibiotic therapy.

Technical specifications

Technical data
Related Products

Technical data

Assay time30 min
Assay stability30 days on board stability / In use stability until the expiration date at storage temperature 2-8 °C
Sample matrix Serum, Plasma
Sample volume10 µL
Measuring range0,5-160 U/ml
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions

The kits are CE-IVD certified and intended for professional use.


References to CLIA Chlamydia trachomatis IgM

  • Cates W Jr, Wasserheit JN. Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol. 1991 Jun;164(6 Pt 2):1771-81. doi: 10.1016/0002-9378(91)90559-a. PMID: 2039031.
    See more on PubMed
  • Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae-- 2014. MMWR Recomm Rep. 2014 Mar 14;63(RR-02):1-19. PMID: 24622331; PMCID: PMC4047970.
    See more on PubMed
  • Nwokolo NC, Dragovic B, Patel S, Tong CY, Barker G, Radcliffe K. 2015 UK national guideline for the management of infection with Chlamydia trachomatis. Int J STD AIDS. 2016 Mar;27(4):251-67. doi: 10.1177/0956462415615443. Epub 2015 Nov 4. PMID: 26538553.
    See more on PubMed
  • Peipert JF. Clinical practice. Genital chlamydial infections. N Engl J Med. 2003 Dec 18;349(25):2424-30. doi: 10.1056/NEJMcp030542. PMID: 14681509.
    See more on PubMed
  • Blas MM, Canchihuaman FA, Alva IE, Hawes SE. Pregnancy outcomes in women infected with Chlamydia trachomatis: a population-based cohort study in Washington State. Sex Transm Infect. 2007 Jul;83(4):314-8. doi: 10.1136/sti.2006.022665. Epub 2007 Mar 7. PMID: 17344249; PMCID: PMC2598687.
    See more on PubMed
  • Zhu H, Shen Z, Luo H, Zhang W, Zhu X. Chlamydia Trachomatis Infection- Associated Risk of Cervical Cancer: A Meta-Analysis. Medicine (Baltimore). 2016 Mar;95(13):e3077. doi: 10.1097/MD.0000000000003077. PMID: 27043670; PMCID: PMC4998531.
    See more on PubMed
  • Silva J, Cerqueira F, Medeiros R. Chlamydia trachomatis infection: implications for HPV status and cervical cancer. Arch Gynecol Obstet. 2014 Apr;289(4):715-23. doi: 10.1007/s00404-013-3122-3. Epub 2013 Dec 18. PMID: 24346121.
    See more on PubMed

Related Products


Safety information

Declaration of conformity

EC Certificate

Find documents for the lot

Do you want to learn more about products? We're here for you.

Please fill in
all fields
marked *